Европска Унија - Исландски - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19f - pneumococcal infections; immunization - bóluefni - virkt ónæmisaðgerðir gegn innrásarsjúkdómum og bráðum miðtaugabólgu af völdum streptococcus pneumoniae hjá ungbörnum og börnum frá sex vikum upp í fimm ára aldur. sjá kafla 4. 4 og 5. 1 í upplýsingum um vörur til að fá upplýsingar um vernd gegn tilteknum sermigerðum pneumokokkum. notkun synflorix ætti að vera ákveðin á grundvelli opinbera tillögur að taka tillit áhrif innrásar sjúkdóminn í mismunandi aldri tekur eins og l serotype faraldsfræði í mismunandi landsvæðum.

Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - lifrarbólgu b yfirborðsmótefnavaki - stungulyf, dreifa

Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - pertussis toxoid; filamentous haemagglutinin; pertactin; diphtheria toxoid; tetanus toxoid - stungulyf, dreifa - áfyllt sprauta

Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - diphtheria toxoid; tetanus toxoid; pertussis toxoid; filamentous haemagglutinin; pertactin; poliovirus inactivated type 1; poliovirus inactivated type 2; poliovirus inactivated type 3 - stungulyf, dreifa - áfyllt sprauta

Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - varicella-zoster virus - stungulyfsstofn og leysir, lausn - 2.000 pfu bóluefni

Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - sevofluranum inn - innöndunargufa, gegndreyptur stabbi - 100 %

Европска Унија - Исландски - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cystic fibrosis - Önnur öndunarfæri - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 og 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 og 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Европска Унија - Исландски - EMA (European Medicines Agency)

biocryst ireland limited - berotralstat dihydrochloride - ofsabjúgur, arfgengur - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Европска Унија - Исландски - EMA (European Medicines Agency)

forte healthcare limited - flúoxetín - sálgreiningarefni - hundar - sem aðstoð við meðferð á aðskilnaðarsjúkdómum hjá hundum sem koma fram við eyðileggingu og óviðeigandi hegðun (vöðvun og óviðeigandi hægðatregða og / eða þvaglát) og aðeins í samsetningu með hegðunarbreytingum.

Европска Унија - Исландски - EMA (European Medicines Agency)

teva b.v. - doxórúbicín hýdróklóríð - brjóstakrabbamein - Æxlishemjandi lyf - myocet liposomal, ásamt cýklófosfamíði, er ætlað fyrir fyrsta lína meðferð brjóstakrabbamein í fullorðinn konur.